Extended Data Fig. 5: Drug dose response curves of lorlatinib analogs against Ba/F3 ALK mutation models. | Nature Cancer

Extended Data Fig. 5: Drug dose response curves of lorlatinib analogs against Ba/F3 ALK mutation models.

From: Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer

Extended Data Fig. 5

Cell viability assays performed with Ba/F3 cells expressing EML4-ALK with the indicated compound mutations treated with 6 LAs or lorlatinib for 48 hours. The viabilities were measured with CellTiter-Glo assay. These data correspond to the heatmap in Fig. 2D and dot plots in Extended Data Fig. 4C. The experiments were performed once.

Back to article page